Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1071 participants.

Also called NCT01033071

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,071 participants (enrolled count) (from the registry)
Sponsor
  • Takeda Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01033071
  • WHO UTN U1111-1112-4298
Other papers using this trial's data
  • Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension Hypertension (Dallas, Tex. : 1979), 2012-08 DOI, PubMed 22710649

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01033071. Randomized; quadruple masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2010-10 (actual). Results posted on 2012-02-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.
Condition
Essential Hypertension
Intervention (Drug)
Azilsartan medoxomil and chlorthalidone
Intervention (Drug)
Azilsartan medoxomil and chlorthalidone
Intervention (Drug)
Olmesartan medoxomil and hydrochlorothiazide
Lead sponsor
Takeda (class: industry)

Record details

Record id
cardio:ct-nct01033071
Content hash
8d5f62ae070237de13d7d9c18a917ee1f24d1dd08f97bd403fce2046585064a6